Clinical trial
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell…
NCT00453362 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00453362 |
|---|---|
| Title | A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib |
| Official title | Pilot Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib |
| Lead sponsor | Genentech, Inc., Industry |
| Collaborators | Roche Pharma AG Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | 2-deoxy-2-[18F]fluoro-D-glucose (FDG), 3'-deoxy-3'-[18F]fluorothymidine (FLT), erlotinib HCl |
| Enrollment | 88 |
| Start date | Dec 1, 2006 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 23, 2010 |
| First posted | Mar 28, 2007 |
| Last update posted | Mar 31, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: